AlphAIalphai — Financial news for AI agents
stocktwits.comAUG 221 min read$IBRX

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

ImmunityBio (IBRX) shares rose 1% in overnight trading ahead of Tuesday's earnings report. The company expects to narrow losses in 2025, with revenue projected to rise to $113.29 million. Anktiva, its lead immunotherapy, saw strong commercial traction, with 2025 net product revenue up 700% to $113 million. Founder Patrick Soon-Shiong highlighted Anktiva's potential in media appearances, citing positive clinical trial results and FDA remarks.

Original reporting
stocktwits.com
Published Aug 22, 2026, 11:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 7:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$IBRX
Bullish
medium confidence
Mentioned
$IBRX
Relevance
4/10
alphai data visualization · based on stocktwits.com
Decision brief

The 30-second read

$IBRXBullishLow
01

Why it matters

The article highlights investor enthusiasm but provides no fresh earnings numbers or regulatory decisions, limiting actionable insight.

02

Market read

Pre‑earnings price movement driven by media buzz; no new material information disclosed.

03

What to watch

Potential regulatory delays or trial setbacks not discussed.

Relevance 4/10Novelty 2/10Timing: pre‑market Tuesday

Background

ImmunityBio (IBRX) is a micro‑cap biotech focused on the IL‑15 immunotherapy Anktiva, with founder Patrick Soon‑Shiong promoting the drug in media appearances.

Company-level read

Ticker impact

$IBRXBullishMedium confidence
Context

IBRX shares rose 1% pre‑market ahead of its Tuesday full‑year 2025 earnings report, driven by weekend buzz around its lead drug Anktiva.

Expected impact

Modest upside potential in the next trading session if earnings meet expectations.

Evidence & confidence

The article reports only investor sentiment and forward‑looking estimates, not a primary disclosure.

Market effects

Sector

Positive sentiment may spill over to other biotech firms developing IL‑15 therapies.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Without new data, the rally could be speculative and reverse after earnings.

Key entities

  • company
    ImmunityBio, Inc.

    Biotech firm developing Anktiva.

  • person
    Patrick Soon‑Shiong

    Founder and executive chairman of ImmunityBio.

Read at source← All news

Related articles

AUG 23
$SLSHighAI 8/10

SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their cancer vaccine, Intismeran Autogene, boosting shares. Analysts raised sales forecasts and approval probabilities. Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are also in focus due to their oncology work. MRNA surged 177%, MRK gained 13%, and other related stocks saw significant moves.

stocktwits.com2 min
AUG 21
$CAPRLow

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

prnewswire.com2 min
AUG 4
$IBRXMedAI 8/10

ImmunityBio, Inc. (IBRX): Results of Operations and Financial Condition

ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million • Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth con

SEC EDGAR 8-K6 min
JUL 30
$IBRXMedAI 8/10

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - ImmunityBio

Emirates Drug Establishment approved ImmunityBio’s (NASDAQ:IBRX) ANKTIVA in the UAE for BCG-unresponsive non-muscle invasive bladder cancer, allowing a 0.4 mg intravesical dose with BCG across the full NMIBC spectrum. It also approved a 1.2 mg subcutaneous dose with checkpoint inhibitors for metastatic NSCLC. QUILT-3.032 reported 71% CIS complete response; QUILT-3.055 median OS was 14.6 months. IBRX shares rose 5.49% to $7.20.

benzinga.com3 min